위암 치료제 시장 : 분자 유형, 화학요법 라인, 투여 경로별 - 세계 예측(2025-2030년)

The Gastric Cancer Drugs Market was valued at USD 3.83 billion in 2023, expected to reach USD 4.06 billion in 2024, and is projected to grow at a CAGR of 6.14%, to USD 5.81 billion by 2030.

The scope of gastric cancer drugs encompasses the development, production, and application of therapies designed to treat gastric cancer, which affects the stomach's mucosal tissue. This includes chemotherapy, targeted therapy, and immunotherapy drugs. The increasing necessity for these drugs is driven by the rising incidence of gastric cancer globally, necessitating more effective treatments to improve patient survival rates and life quality. Applications primarily focus on healthcare providers, including hospitals and clinics, along with research institutions exploring advancements in treatment techniques. End-use scope extends to pharmaceutical companies, research bodies, and medical institutions, aiming to integrate advanced treatments into cancer care protocols.

Market insights reveal key growth factors such as heightened awareness of gastric cancer symptoms, advancements in biotechnology enhancing drug efficacy, and the availability of funding for cancer research. The Asia-Pacific region, particularly China and Japan, presents significant potential due to high prevalence rates and increasing healthcare expenditure. Recommendations to capitalize on opportunities include strategic partnerships between pharmaceutical firms and biotech startups, and increased investment in R&D for novel treatment options.

However, limitations exist in the form of substantial R&D costs and stringent regulatory approvals that can delay drug launches. Additionally, the market faces challenges such as drug resistance and variability in treatment responses among patients. To overcome these, focusing on personalized medicine and implementing adaptive clinical trials could be highly beneficial.

Areas ripe for innovation include the development of combination therapies that synergistically enhance treatment effectiveness, as well as leveraging AI for early diagnosis and personalized treatment plans. Exploiting advancements in genomics to understand genetic predispositions could also foster product differentiation. Overall, the gastric cancer drugs market is competitive yet promising, with significant scope for growth through technological innovations and strategic alliances, provided that businesses can navigate the regulatory landscape and invest in patient-centric solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gastric Cancer Drugs Market

The Gastric Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidences of the stomach cancer with the increasing number of obesity cases and smoking population
  • Introduction of novel therapies for metastatic stomach cancer
  • Increase in awareness about the symptoms and causes of gastric cancer
• Market Restraints
  • Stringent regulations and policies for approval of the drugs
• Market Opportunities
  • Accelerating research and development activities in the drugs for gastic cancer
  • Rapid adoption of biosimilars in oncology
• Market Challenges
  • Availability of the counterfeit drugs

Porter's Five Forces: A Strategic Tool for Navigating the Gastric Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gastric Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gastric Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gastric Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gastric Cancer Drugs Market

A detailed market share analysis in the Gastric Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gastric Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gastric Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gastric Cancer Drugs Market

A strategic analysis of the Gastric Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gastric Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., ASLAN Pharmaceuticals Pte Ltd, AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., SELLAS Life Sciences Group, Inc., Taiho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Gastric Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Molecule Type, market is studied across Biologics and Small Molecules.
• Based on Lines of Chemotherapy, market is studied across First-line Chemotherapy and Second-line Chemotherapy.
• Based on Route of Administration, market is studied across Oral and Parenteral.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidences of the stomach cancer with the increasing number of obesity cases and smoking population
    • 5.1.1.2. Introduction of novel therapies for metastatic stomach cancer
    • 5.1.1.3. Increase in awareness about the symptoms and causes of gastric cancer
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent regulations and policies for approval of the drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Accelerating research and development activities in the drugs for gastic cancer
    • 5.1.3.2. Rapid adoption of biosimilars in oncology
  • 5.1.4. Challenges
    • 5.1.4.1. Availability of the counterfeit drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Gastric Cancer Drugs Market, by Molecule Type

• 6.1. Introduction
• 6.2. Biologics
• 6.3. Small Molecules

7. Gastric Cancer Drugs Market, by Lines of Chemotherapy

• 7.1. Introduction
• 7.2. First-line Chemotherapy
• 7.3. Second-line Chemotherapy

8. Gastric Cancer Drugs Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral

9. Americas Gastric Cancer Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Gastric Cancer Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Gastric Cancer Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amgen Inc.
• 2. ASLAN Pharmaceuticals Pte Ltd
• 3. AstraZeneca PLC
• 4. Bayer AG
• 5. Bristol Myers Squibb Company
• 6. Eli Lilly and Company
• 7. F. Hoffmann-La Roche AG
• 8. GlaxoSmithKline PLC
• 9. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• 10. Merck & Co., Inc.
• 11. Novartis AG
• 12. Pfizer Inc.
• 13. SELLAS Life Sciences Group, Inc.
• 14. Taiho Pharmaceutical Co., Ltd.
• 15. Takeda Pharmaceutical Company Limited